Article

Academic Perspectives in Non-Small Cell Lung Cancer

In this clinical case review, academic experts share insights into the disease management of patients with NSCLC, discuss factors impacting treatment selection and sequencing strategies, and evaluate the evolving landscape of immunotherapy-based regimens.

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Related Content
NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI
December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Solange Peters, MD, PhD
December 30th 2024

How a Never-Wavering Enthusiasm Changed Lung Cancer Care for the Better

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

NSCLC | stock.adobe.com
December 24th 2024

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC

FDA
December 23rd 2024

FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC